Alzheimer’s Disease/Dementia News

NEW ORLEANS – Clinicians need to do a better job screening for mild cognitive impairment, Brent P. Forester, MD, MSc, said at the American Psychiatric Association annual meeting.

NEW ORLEANS – The American Psychiatric Association DSM steering committee gathered at the APA annual meeting to review proposed changes to the manual, committee chair Paul S. Appelbaum, MD, said.

NEW ORLEANS – For the first time in 3 years, the American Psychiatric Association will host its annual meeting in person, May 21 to 25 in New Orleans, with social determinants of mental health as the conference theme.

People with higher levels of antioxidants in their blood may be less likely to develop dementia, researchers reported in Neurology.

Alzamend Neuro Inc. has announced the launch of a phase 2A trial for its AL001 treatment for mild to moderate Alzheimer’s dementia.

The Indian Health Service has announced it will allocate $5 million in funding toward resources to address Alzheimer’s disease among tribal communities.

The FDA announced it will review a resubmitted supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

The FDA granted breakthrough device designation and permitted marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer’s disease.

The FDA has granted fast track designation for Vaxxinity Inc.’s UB-311, an anti-amyloid beta immunotherapeutic vaccine, for the treatment of Alzheimer’s disease.

The FDA and European Commission have both granted orphan drug designation to AviadoBio for its new gene therapy to treat frontotemporal dementia, according to a company press release.